News / Taiwan / economic_daily
Oasmia Pharmaceutical Shares Surge to Limit Up as Market Plunges Amid Novartis ADC Deal
Health Technology · Biotechnology · economic_daily · 2026-11-16
4174, 8463
Despite a massive 2,600-point drop in the Taiwan stock market, Oasmia Pharmaceutical shares hit the daily limit after announcing a major ADC platform licensing deal with Novartis.
What Happened
Market Sell-off: The Taiwan stock market faced a severe downturn on the 16th, plummeting over 2,600 points to close at 41,040.08, driven by political and business tensions surrounding the resignation of NVIDIA's former CEO.
Oasmia's Resilience: Defying the broader market crash, Oasmia Pharmaceutical shares defied the trend and hit the daily limit, closing at 71.3 TWD, marking a two-year high. The stock's performance was fueled by positive news regarding a strategic international partnership.
ADC Platform Partnership: Oasmia has entered into a licensing agreement with Novartis to utilize its proprietary Antibody-Drug Conjugate (ADC) platform. The collaboration aims to develop next-generation cancer therapies by combining Oasmia's technology with Novartis's novel drug payloads.
Financial Upside: The deal includes an upfront payment of $30 million, with total potential milestone payments exceeding $2 billion based on development and commercialization progress. Oasmia also retains the right to receive royalties on net sales of products resulting from the collaboration.